OUR SCIENCE

A different therapeutic thesis for immune-cold, therapy-resistant tumors.

Why TABI™?

ICI

ADC

Release immune inhibition

Poor response in immune-cold tumors

Established class profile

Deliver cytotoxic payload

Payload-related toxicities

Resistance and relapse

TCE / CAR-T

Redirect cytotoxic T cells

Immune-cold, suppressive TME limits efficacy

CRS / immune toxicities

TABI™

Reprogram local immune context

Rreclinical — clinical translation not yet established

Tumor localization + conditional masking

Approach

MOA

Limitation

Safety